Skip to main content

Table 1 Baseline characteristics of patients included in the CANVAS Trial

From: Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

Description

Canagliflozin

(N = 2472)

Placebo

(N = 1241)

Total

(N = 3713)

Age (years)

62.8 (7.9)

62.6 (7.8)

62.7 (7.9)

Males, N (%)

1653 (66.9)

833 (67.1)

2486 (67.0)

Race, N (%)

 Caucasian

1992 (80.6)

997 (80.3)

2989 (80.5)

 Black

60 (2.4)

32 (2.6)

92 (2.5)

 Asian

257 (10.4)

134 (10.8)

391 (10.5)

 Others

163 (6.6)

78 (6.3)

241 (6.5)

Smoker (yes)

429 (17.4)

250 (20.1)

679 (18.3)

Previous CVD history (yes)

1474 (59.6)

730 (58.8)

2204 (59.4)

eGFR (ml/min/1.73m2)

79.6 (17.4)

79.4 (17.3)

79.5 (17.3)

Glycated hemoglobin (%)

8.2 (0.9)

8.2 (0.9)

8.2 (0.9)

Systolic BP (mmHg)

136.3 (15.9)

137.2 (15.8)

136.6 (15.9)

UACR (mg/g)

11.7 [6.5 to 35.0]

11.6 [6.3 to 36.5]

11.7 [6.4 to 35.7]

Weight (kg)

93.6 (20.9)

92.9 (20.7)

93.4 (20.8)

Hemoglobin (g/L)

140.6 (14.5)

140.0 (14.4)

140.4 (14.5)

Albumin (g/L)

41.0 (3.3)

41.0 (3.2)

41.0 (3.2)

HDL-cholesterol (mmol/L)

1.2 (0.3)

1.2 (0.3)

1.2 (0.3)

LDL-cholesterol (mmol/L)

2.3 (0.9)

2.3 (0.9)

2.3 (0.9)

Uric acid (umol/L)

351.5 (91.8)

350.5 (98.5)

351.2 (94.1)

Potassium (mmol/L)

4.4 (0.5)

4.4 (0.4)

4.4 (0.5)

TNFR-1 (ng/ml)

2.6 [2.1 to 3.2]

2.6 [2.1 to 3.1]

2.6 [2.1 to 3.2]

TNFR-2 (ng/ml)

9.7 [7.8 to 12.0]

9.6 [7.9 to 12.1]

9.7 [7.9 to 12.0]

KIM-1 (ng/ml)

0.1 [0.1 to 0.2]

0.1 [0.1 to 0.2]

0.1 [0.1 to 0.2]

GDF-15 (ng/ml)

1.8 [1.2 to 2.5]

1.8 [1.2 to 2.5]

1.8 [1.2 to 2.5]

MMP-7 (ng/ml)

6.1 [4.7 to 8.4]

6.2 [4.7 to 8.4]

6.2 [4.7 to 8.4]

IL-6 (pg/ml)

1.6 [1.2 to 2.4]

1.6 [1.2 to 2.3]

1.6 [1.2 to 2.4]

uMCP-1 (ng/ml)

0.2 [0.1 to 0.3]

0.2 [0.1 to 0.3]

0.2 [0.1 to 0.3]

uEGF (ng/ml)

4.6 [2.6 to 7.8]

4.6 [2.6 to 7.9]

4.6 [2.6 to 7.8]

uMCP-1/Cr (ng/g)

191.0

[121.8 to 312.7]

193.0

[123.0 to 344.1]

191.7

[122.6 to 321.1]

uEGF/Cr (ng/g)

5063.3

[3345.4 to 7865.9]

5198.9

[3450.0 to 7658.5]

5097.4

[3365.7 to 7811.7]

  1. For numerical variables which are normally distributed, data is presented as mean (SD). For UACR, TNFR-1, TNFR-2, KIM-1, GDF-15, MMP-7, IL-6, uMCP-1,uEGF, uMCP-1/Cr, uEGF/Cr with a skewed distribution, median [IQR] is presented. Categorical variables are presented as frequency (%)
  2. Estimated glomerular filtration rate (eGFR) was estimated according to the Chronic Kidney Disease Epidemiology Collaboration formula as per the CANVAS trial protocol
  3. BP, blood pressure; UACR, urinary-albumin to urinary-creatinine ratio; HDL, high-density-lipoprotein; LDL, low-density-lipoprotein.; TNFR, tumor necrosis factor receptor; KIM, kidney injury molecule; GDF, growth differentiation factor; MMP, matrix metallopeptidase; IL, interleukin; uMCP, urinary monocyte chemoattractant protein; uEGF, urinary epidermal growth factor; uMCP-1/Cr, urinary monocyte chemoattractant protein-1 to urinary creatinine ratio; uEGF/Cr, urinary epidermal growth factor to urinary creatinine ratio
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840